# US 2021/0268128 A1 · Fluorescent nanoparticles and imaging uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0268128 A1
- Document ID: US20210268128A1
- Status: Published application
- Kind: A1
- Application number: 17/253,959
- Filed: 2019-07-09
- Published: 2021-09-02
- Earliest claimed: 2018-07-10
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Stefan Harmsen
- Web page: https://patentgrep.com/patent/US20210268128A1

## CPC

- A61K 49/0041: {Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal (in vivo G01N)}
- A61K 49/0093: {Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle}
- A61K 49/005: {characterised by the carrier molecule carrying the fluorescent agent}
- C01B 33/18: Preparation of finely divided silica neither in sol nor in gel form; After-treatment thereof (preparation of aerogels by dehydrating gels C01B33/158; treatment to enhance the pigmenting or filling properties C09C)
- G01N 33/52: Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper {and including single- and multilayer analytical elements (immunological elements G01N33/54386; involving labelled immunochemicals G01N33/58; for haemoglobin or occult blood G01N33/72)}
- G01N 33/54346: {Nanoparticles}
- G01N 33/552: Glass or silica
- G01N 33/5753: of the stomach or small intestine
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C01B: NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; {METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Biodegradable fluorescent silica nanoparticle (FSN) are provided for in vivo imaging, particularly of cancerous and precancerous lesions in the gastrointestinal tract. The FSN are comprised of (a) a dye that fluoresces in the near infrared spectrum which is (i) covalently joined to a silane, and (ii) distributed throughout the nanoparticle; and (b) silica distributed throughout the nanoparticle. The surface may be coated with hydroxyl-terminated PEG, which is shown to reduce uptake of the nanoparticles by the liver. The dyes provide for sensitive detection of clinically relevant lesions, and are biodegradable.

## Claims

### Claim 1

A biodegradable fluorescent silica nanoparticle (FSN) for in vivo imaging, wherein the FSN is of from about 25 nm to about 200 nm in diameter, comprised of:
(a) a dye that fluoresces in the near infrared spectrum which is (i) covalently joined to a silane, and (ii) distributed throughout the nanoparticle; and
(b) silica distributed throughout the nanoparticle.

### Claim 2 (depends on 1)

The FSN of claim 1, wherein the FSN is coated with one or more of hydroxy-terminated polyethylene glycol (PEG); methoxy-terminated polyethylene glycol (PEG);
and targeting moiety-terminated PEG.

### Claim at position 3

3-4. (canceled)

### Claim 5 (depends on 2)

The FSN of claim 2, wherein the PEG is covalently linked to the surface of the FSN by sulfhydryl bonds.

### Claim 6 (depends on 2)

The FSN of claim 2, wherein the PEG is from about 250 da to about 10,000 da in size.

### Claim 7 (depends on 2)

The FSN of claim 2, wherein an FSN comprises from about 104 to about 106 PEG moieties.

### Claim 8 (depends on 1)

The FSN of claim 1, wherein the dye fluoresces in the NIR I window at a wavelength of from about 680 nm to about 900 nm.

### Claim 9 (depends on 1)

The FSN of claim 1, wherein the dye fluoresces in the NIR II window at a wavelength of from about 900 nm to about 2500 nm.

### Claim 10 (depends on 1)

The FSN of claim 1 wherein the detection limit is from about 30×10−‥M to about 10−13 M on a per particle basis.

### Claim 11 (depends on 1)

The FSN of claim 1 wherein the FSN is fully biodegraded after about 3 to about 6 months following administration.

### Claim 12 (depends on 1)

The FSN of claim 1 wherein the FSN is fully biodegraded after about 1 to about 6 months following administration due to incorporation of labile bonds.

### Claim 13 (depends on 1)

A pharmaceutical composition, comprising:
an FSN of claim 1; and
a pharmaceutically acceptable excipient.

### Claim 14 (depends on 13)

A method of detecting dysplastic lesions in the gastrointestinal tract, the method comprising:
administering a pharmaceutical composition of claim 13 to an individual; and following a period of time sufficient for enhanced permeability and retention effect (ERR) to concentrate the FSN at cancerous or pre-cancerous lesions; detecting the presence of the FSN, wherein increased concentration relative to normal tissue of the FSN is indicative of a premalignant or malignant lesion.

### Claim 15 (depends on 14)

The method of claim 14, wherein the FSN is administered intravenously, intraluminally, or topically.

### Claim at position 15

16-17. (canceled)

### Claim 18 (depends on 14)

The method of claim 14, wherein the period of time sufficient to concentrate the FSN is from about 15 minutes to about 24 hours.

### Claim 19 (depends on 14)

The method of claim 14, wherein detection is accomplished with a NIRF or combined NIRF and white light camera.

### Claim 20 (depends on 14)

The method of claim 14, wherein detection is used to guide endoscopic surveillance.

### Claim 21 (depends on 14)

The method of claim 14, wherein detection is used to guide endoscopic intervention or biopsy.

### Claim 22 (depends on 14)

The method of claim 14, wherein detection is used to guide laparoscopic intervention

### Claim 23 (depends on 14)

The method of claim 14, wherein detection of the FSN is used to guide surgery of the lesion.
